Septerna, Inc. (NASDAQ: SEPN) reported that its President and Chief Operating Officer, Elizabeth Bhatt, sold 4,000 shares of common stock on February 18, 2026, for aggregate proceeds of $115,860. The disposition occurred in two tranches and was completed at weighted average prices ranging from $28.4594 to $29.5831 per share.
The sales were made pursuant to a Rule 10b5-1 trading plan that Bhatt adopted on October 20, 2025. In a concurrent move on the same date, Bhatt exercised stock options to purchase 4,000 shares of Septerna common stock at an exercise price of $6.81 per share, representing a total exercise cost of $27,240.
After these transactions, Bhatt directly holds 174,209 shares of Septerna. The company is cited as having a market value of $1.22 billion and carries a "GREAT" financial health rating according to InvestingPro, which is noted as providing additional ProTips for investors seeking more detailed analysis.
These insider transactions follow a period of substantial share-price appreciation for Septerna, with the stock having risen approximately 370% over the last year. The company has a number of developments and institutional touches that have coincided with this move in valuation.
On the clinical front, Septerna has scheduled a presentation of Phase 1 data for its lead oral small molecule candidate SEP-631 at the American Academy of Allergy Asthma & Immunology Annual Meeting in 2026. SEP-631 is being developed for chronic spontaneous urticaria and other mast cell-driven diseases.
Market coverage of Septerna has expanded recently. H.C. Wainwright increased its price target to $35 and kept a Buy rating after adjusting its valuation model. Jones Trading initiated coverage with a Buy rating and a $43 price target. Raymond James began coverage with a Strong Buy rating and a $38 price target.
In corporate leadership news, Septerna appointed Mark A. Wilson as Chief Legal Officer. The company noted his more than 25 years of experience and his prior role at Nektar Therapeutics.
Taken together, the insider transaction, option exercise, upcoming clinical data presentation, analyst re-ratings, and a senior legal hire represent a cluster of company actions and market signals that investors and observers may track as Septerna advances its GPCR drug discovery platform.
Key developments at a glance
- Elizabeth Bhatt sold 4,000 shares on February 18, 2026, for $115,860 in two tranches at weighted average prices of $28.4594 to $29.5831.
- Bhatt exercised options to acquire 4,000 shares at $6.81 per share the same day for $27,240.
- Septerna will present Phase 1 SEP-631 data at the AAAAI Annual Meeting in 2026 and has received fresh analyst coverage and price-target revisions.